LifeCell Corporation Schedules First Quarter 2005 Financial Results Conference Call; April 26, 2005 At 10:00 A.M. Eastern

BRANCHBURG, N.J., April 19 /PRNewswire-FirstCall/ -- LifeCell Corporation , today announced that Paul Thomas, President and Chief Executive Officer, will host a conference call on Tuesday, April 26, 2005 at 10:00 a.m. Eastern, to discuss the Company's operating results for its first quarter 2005. Operating results will be released at 8:00 a.m. Eastern that day.

The dial-in number for the live call is (888) 202-2422/domestic or (913) 981-5592/international. A simultaneous webcast of the call will be available via LifeCell's website at http://www.lifecell.com/ Corporate Information - Investor Relations. The call will be archived on the Company's website for twelve months.

A recording of the live-call will be available through May 3, 2005. The dial-in number to listen to the recording is (719) 457-0820. The replay access code is 5450094.

About LifeCell

LifeCell develops and markets products made from human tissue for use in reconstructive, urogynecologic and orthopedic surgical procedures. The Company's patented technology produces a unique regenerative human tissue matrix -- a complex three-dimensional structure that contains an array of proteins, growth factor binding sites and vascular channels -- that provides a complete template for the regeneration of normal human tissue. LifeCell's current products include: AlloDerm(R) for plastic reconstructive, general surgical, burn and periodontal procedures; Cymetra(R), a particulate form of AlloDerm suitable for injection; Repliform(R) for urogynecologic surgical procedures; GraftJacket(R) and GraftJacket(R) Xpress for orthopedic applications and lower extremity wounds; and AlloCraft(TM)DBM, for bone grafting procedures. LifeCell markets AlloDerm for plastic reconstructive, general surgical and burn applications through its direct sales organization. The Company's strategic sales and marketing partners include: Boston Scientific for Repliform, Wright Medical Group, Inc. for GraftJacket, Stryker Corporation for AlloCraftDBM and BioHorizons for periodontal applications of AlloDerm. The Company's research and development initiatives include programs focused on extending the use of its regenerative tissue matrix products into new surgical applications, leveraging its core technology to other tissues and expanding its product line in the rapidly growing biologic market. Visit the LifeCell website at http://www.lifecell.com/.

CONTACT: Steven T. Sobieski, Chief Financial Officer of LifeCellCorporation, +1-908-947-1106, ssobieski@lifecell.com; or Kevin McGrath ofCameron Associates, +1-212-245-8800, kevin@cameronassoc.com

Web site: http://www.lifecell.com/